Literature DB >> 2555307

Activation and immortalization of leukaemic B cells by Epstein-Barr virus.

E V Walls1, M G Doyle, K K Patel, M J Allday, D Catovsky, D H Crawford.   

Abstract

We have studied the responses of chronic leukaemic B cells to infection by Epstein-Barr virus (EBV). Our results define one population of B lymphocytes, represented by prolymphocytic leukaemic (PLL) cells, which are highly susceptible to immortalization by EBV. Another B-cell type, represented by chronic lymphocytic leukaemic (CLL) cells, can be readily infected by the virus but is resistant to immortalization. Comparative studies of viral and cellular related events early after infection in these 2 cell types reveal that both express the EB viral nuclear antigen (EBNA) complex, but the immortalization-resistant CLL cells fail to express the latent membrane protein (LMP), which can be detected in PLL cells 48 hr after infection. Circularization of the linear viral genome could be detected at 7 days post infection in the PLL cells, but only in 2 out of 4 CLL cells tested. Both CLL and PLL cells show increased surface expression of CD23 and HLA-DR molecules after infection but, whereas PLL cells show an increase in size, together with RNA and DNA synthesis indicative of cell cycle progression, CLL cells appear to be arrested in the G1/S phase of the cycle. The results suggest that the outcome of infection by EBV is determined by the nature of the target cell rather than by random virus-related events. The correlation between the block in immortalization of CLL cells and their failure to express LMP suggests that expression of this protein is essential for in vitro immortalization of B cells. The failure to detect circularization in some EBV-infected CLL cells suggests that this, as well as LMP expression, may be dependent on prior activation of the B cell by EBV, an event which may vary between the different CLL samples tested.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555307     DOI: 10.1002/ijc.2910440517

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  EBV infection induces expression of the transcription factors ATF-2/c-Jun in B lymphocytes but not in B-CLL cells.

Authors:  Kentaro Bandobashi; Anquan Liu; Noémi Nagy; Loránd L Kis; Jun Nishikawa; Magnus Björkholm; George Klein; Eva Klein
Journal:  Virus Genes       Date:  2005-05       Impact factor: 2.332

2.  An efficient method for routine Epstein-Barr virus immortalization of human B lymphocytes.

Authors:  F E Wall; R D Henkel; M P Stern; H B Jenson; M P Moyer
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-02       Impact factor: 2.416

3.  Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells.

Authors:  M J Allday; P J Farrell
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

4.  In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40.

Authors:  D H Crawford; D Catovsky
Journal:  Immunology       Date:  1993-09       Impact factor: 7.397

5.  Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity.

Authors:  R Fåhraeus; L Palmqvist; A Nerdstedt; S Farzad; L Rymo; S Laín
Journal:  EMBO J       Date:  1994-12-15       Impact factor: 11.598

6.  Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection.

Authors:  Anders Rosén; Ann-Charlotte Bergh; Peter Gogok; Chamilly Evaldsson; Anna Lanemo Myhrinder; Eva Hellqvist; Abu Rasul; Magnus Björkholm; Mattias Jansson; Larry Mansouri; Anquan Liu; Bin Tean Teh; Richard Rosenquist; Eva Klein
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

7.  EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency.

Authors:  Eva Klein; Noémi Nagy; Abu Eahsan Rasul
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

Review 8.  Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology.

Authors:  Martin Rowe; Gemma L Kelly; Andrew I Bell; Alan B Rickinson
Journal:  Semin Cancer Biol       Date:  2009-07-18       Impact factor: 15.707

9.  Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.

Authors:  Erin Hertlein; Kyle A Beckwith; Gerard Lozanski; Timothy L Chen; William H Towns; Amy J Johnson; Amy Lehman; Amy S Ruppert; Brad Bolon; Leslie Andritsos; Arletta Lozanski; Laura Rassenti; Weiqiang Zhao; Tiina M Jarvinen; Leigha Senter; Carlo M Croce; David E Symer; Albert de la Chapelle; Nyla A Heerema; John C Byrd
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

10.  The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia.

Authors:  Eahsan Rasul; Daniel Salamon; Noemi Nagy; Benjamin Leveau; Ferenc Banati; Kalman Szenthe; Anita Koroknai; Janos Minarovits; George Klein; Eva Klein
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.